Susquehanna International Group, LLP Cel Sci Corp Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$1.05 - $1.5 $4,725 - $6,750	-4,500 Reduced 4.28%	100,700 $106,000
Q2 2024 Aug 15, 2024	SELL	$1.11 - $1.85 $3,996 - $6,660	-3,600 Reduced 3.31%	105,200 $122,000
Q1 2024 May 07, 2024	SELL	$1.63 - $3.08 $88,509 - $167,244	-54,300 Reduced 33.29%	108,800 $207,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $3.07 $128,293 - $368,093	119,900 Added 277.55%	163,100 $443,000
Q3 2023 Nov 14, 2023	SELL	$1.17 - $2.86 $56,979 - $139,282	-48,700 Reduced 52.99%	43,200 $54,000
Q2 2023 Aug 11, 2023	SELL	$2.11 - $2.83 $30,595 - $41,035	-14,500 Reduced 13.63%	91,900 $221,000
Q1 2023 May 16, 2023	SELL	$2.17 - $3.13 $103,292 - $148,988	-47,600 Reduced 30.91%	106,400 $246,000
Q4 2022 Feb 14, 2023	SELL	$1.99 - $3.52 $276,411 - $488,928	-138,900 Reduced 47.42%	154,000 $361,000
Q3 2022 Nov 14, 2022	BUY	$3.09 - $5.23 $92,700 - $156,900	30,000 Added 11.41%	292,900 $905,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.